Long term update on toxicity and survival of a phase II trial of linac-based stereotactic body radiation therapy for low-intermediate risk prostate cancer.

Giuseppe R D'AgostinoMarco BadalamentiSara StefaniniDavide BaldacciniCiro FranzeseLorenzo Lo FaroLuciana Di CristinaVeronica VernierGiacomo ReggioriMarta Scorsetti

Published in: The Prostate (2023)

This long-term update confirms that SBRT is a valid therapeutic strategy for low-intermediate risk PC. RT with VMAT and FFF warrants optimal results in terms of toxicity and disease control.

Keyphrases

prostate cancer
oxidative stress
radiation therapy
radical prostatectomy
randomized controlled trial
open label